IMV Inc. (IMVIF)
OTC PINK OTC PINK Primary Summary
IMV Inc. (IMVIF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has IMV Inc. ever had a stock split?
IMV Inc. Profile
| Biotechnology Industry | Healthcare Sector | Andrew Hall CEO | OTC PINK Exchange | 44974L301 CUSIP |
| CA Country | 63 Employees | - Last Dividend | 13 Dec 2022 Last Split | - IPO Date |
Overview
IMV Inc. stands as a pioneering entity in the realm of clinical-stage immuno-oncology, emphasizing the development of innovative therapies tailored to combat both solid and hematological cancers. Anchored in DPX, its proprietary immune-educating technology platform, IMV Inc. strives to harness the body's immune system to fight cancer effectively. Initially known as Immunovaccine Inc., the company underwent a rebranding phase in May 2018, adopting the name IMV Inc. Since its establishment in 2000, IMV Inc. has made Dartmouth, Canada, its operational base, positioning itself as a frontrunner in the quest for breakthrough cancer treatments and infectious disease immunotherapies.
Products and Services
maveropepimut-S: Serving as IMV Inc.'s flagship drug candidate, maveropepimut-S represents a pioneering DPX-based immunotherapy designed to target survivin-expressing cells. Its potential applicability spans a wide array of cancers, including diffuse large B cell lymphoma, ovarian cancer, and bladder, liver, and MSI-H solid tumors. Currently, maveropepimut-S is undergoing Phase II clinical trials for the aforementioned cancers, in addition to a Phase I clinical trial targeting breast cancer. This diversity in application underscores the drug's versatility and IMV Inc.'s ambitious vision for its development.
DPX-SurMAGE: Another promising endeavor by IMV Inc. is DPX-SurMAGE, which is in a Phase I clinical trial specifically for bladder cancer. This therapy leverages the DPX platform's unique mechanism to stimulate an immune response against cancer cells, illustrating the company's commitment to expanding its portfolio of cancer treatments.
DPX-COVID-19 and DPX-RSV: Venturing beyond the realm of oncology, IMV Inc. is also developing immunotherapies for infectious diseases, including DPX-COVID-19 and DPX-RSV. These projects highlight the company's adaptive approach to leveraging its DPX platform for addressing global health challenges beyond cancer, indicating a broadened scope of its technological and therapeutic ambitions.
